Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Abstract Background A limited number of studies have characterized genomic properties of hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy. Methods Herein, we performed comprehensive molecular characterization of immediate (D-42 to D-1) pre-treatment tumor biopsy specime...

Full description

Bibliographic Details
Main Authors: Jung Yong Hong, Hee Jin Cho, Jason K. Sa, Xiaoqiao Liu, Sang Yun Ha, Taehyang Lee, Hajung Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hee Chul Park, Tae Wook Kang, Hyunchul Rhim, Su Jin Lee, Razvan Cristescu, Jeeyun Lee, Yong Han Paik, Ho Yeong Lim
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Genome Medicine
Subjects:
Carcinoma
Hepatocellular
Pembrolizumab
Biomarkers
Tumor
Online Access:https://doi.org/10.1186/s13073-021-00995-8

Internet

https://doi.org/10.1186/s13073-021-00995-8

Similar Items